Hsu, Miles M <br/><br/>
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.  [electronic resource] 

 -  Clinical genitourinary cancer  06 2019 
 - e618-e626 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review 
<br/><br/><label>ISSN: </label>1938-0682 
<br/><br/><label>Standard No.: </label>10.1016/j.clgc.2019.03.009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>B7-H1 Antigen--antagonists & inhibitors<br/>Carcinoma, Transitional Cell--drug therapy<br/>Clinical Trials as Topic<br/>Humans<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Survival Analysis<br/>Treatment Outcome<br/>Tumor Microenvironment--drug effects<br/>Urologic Neoplasms--drug therapy